<DOC>
	<DOCNO>NCT01868594</DOCNO>
	<brief_summary>The purpose study : - ass clinical efficiency Subetta combine treatment type I diabetes mellitus ; - ass safety Subetta combine treatment type I diabetes mellitus .</brief_summary>
	<brief_title>Clinical Trial Efficiency Safety Subetta Combined Treatment Patients With Type I Diabetes Mellitus</brief_title>
	<detailed_description>Patients type I diabetes mellitus include trial . It concern patient , time trial receive functional ( basal bolus ) insulin therapy type I diabetes mellitus accord acceptable standard therapy , include basal insulin ( use intermediate long acting medication ) alimentary prandial insulin ( short ultra short act medication ) , lack optimal glycemic control ( HbA1c &gt; 7.0 % ) . For patient , include trial ( mainly middle age patient without severe complication diabetes ) , HbA1c &gt; 7.0 % marker show optimal individual goal glycemic control achieve . If patient meet inclusion criterion show non-inclusion criterion he/she randomize one 2 group : Group 1 - group receive standard type I diabetes mellitus therapy + Subetta dose 1 tablet 4 time day ; Group 2 - group receive standard type I diabetes mellitus therapy + Placebo regimen use Subetta . The invented name drug contain basal alimentary insulin unchanged patient whole trial . All patient receive glucometers appropriate glucose test strip , could self monitor blood glucose register data diary . The trial duration 38 week ; main stage trial conduct screening , 4 week ( Visit 2 ) , 12 week ( Visit 3 ) , 24 week ( Visit 4 ) 36 week ( Visit 5 ) . In 1 week randomization onset trial therapy visit study site ( week 8±1 , 18±1 30±1 ) investigator collect data patient 's health complaint ( phone visit ) decide whether necessary arrange unplanned visit site .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Diagnosed type I diabetes mellitus ( accord WHO criterion , 1999 2006 ) . 2 . Disease duration le 6 month . 3 . Patient 's age 18 65 year inclusive . 4 . Level glycosylated hemoglobin 7.0 10.0 % . 5 . Glomerular filtration rate ≥ 60 ml/ min/1.73m^2 . 6 . Stable dose basal insulin last 3 month . ( Permissible fluctuation ±10 % . ) 7 . Usage contraceptive method gender patient reproductive age trial within 30 day end participation trial . 8 . Availability sign patient information sheet ( Informed Consent form ) participation clinical trial . 1 . Acute diabetes mellitus complication 3 month prior inclusion trial ( diabetic ketoacidosis , hyperosmolar hyperglycemic state , lacticemia , severe hypoglycemia hypoglycemic coma ) . 2 . Diabetic retinopathy , preproliferative , proliferative terminal stage ( base result oculist examination screen period 6 month prior trial ) . 3 . Diabetic nephropathy , proteinuria stage , chronic kidney disease 3 , 4 5 stage . 4 . Diabetic microangiopathy : ishemic heart disease ( medical history sudden coronary death successful reanimation , medical history myocardial infarction , stable exertional angina III IV FC ; instable angina ; postinfarction cardiosclerosis ; chronic heart failure III IV FC ) ; cerebrovascular disease ( medical history acute cerebrovascular accident ; progressive vascular leukoencephalopathy ; vascular dementia ) ; chronic obliterative peripheral vascular disease ( clinically significant ) ; diabetic neuroosteoarthropathy ; diabetic foot ( clinically significant ) . 5 . Heart rhythm disorder : IIIII atrioventricular block ; sick sinus syndrome ; long QT interval syndrome ; complete leave bundle branch block ; block 2/3 bundle branch ; WPW syndrome ; ventricular arrhythmia III grade accord LaunWolf ; paroxysmal supraventricular tachycardia ; paroxysmal/recurrent ventricular tachycardia ; atrial flutter fibrillation ; ventricular flutter fibrillation ; heart pacemaker implant . 6 . Uncontrolled arterial hypertension characterize follow blood tension value : systolic blood pressure 160 mm Hg and/or diastolic blood pressure 100 mm Hg . 7 . Severe concomitant pathology include clinically significant cardiovascular disease III IV functional class ( accord New York Heart Association classification , 1964 ) , nervous endocrine system disease , include morbid obesity ( body build index≥40.0 kg/m2 ) , renal insufficiency , liver failure . 8 . Medical history pancreatectomy transplantation pancreatic/islet cell . 9 . Medical history renal transplantation . 10 . Malignant neoplasms/suspected malignant neoplasm . 11 . Exacerbations decompensation chronic disease affect patient 's ability participate clinical trial . 12 . Level fast triglyceride &gt; 5.64 mmol/L . 13 . Medical history bariatric surgical operation . 14 . Medical history polyvalent allergy . 15 . Allergy/ intolerance component medication use treatment . 16 . Intake medicine list section `` Prohibited concomitant treatment '' 3 month prior inclusion trial . 17 . Pregnancy , breastfeed . 18 . Drug addiction , alcohol usage amount exceed 2 unit alcohol per day . 19 . Mental disorder patient . 20 . Night work . 21 . Participation clinical trial course 3 month prior inclusion trial . 22 . Patients , investigator 's point view , fail comply observation requirement trial intake regimen investigate medicine . 23 . Other factor impede patient 's participation trial ( example , plan business trip journey ) . 24 . Patient relate research personnel investigative site , directly involve trial immediate relative researcher . The immediate relative include husband/wife , parent , child brother ( sister ) , regardless whether natural adopt . 25 . Patient work OOO `` NPF `` Materia Medica Holding '' ( i.e . company 's employee , temporary contract worker appoint official responsible carry research ) immediate relative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Combined treatment patient type I diabetes mellitus</keyword>
</DOC>